Impact of Urolithin A (Mitopure) on Mitochondrial Quality in Muscle of Frail Older Adults

Last updated: September 25, 2024
Sponsor: Amazentis SA
Overall Status: Active - Recruiting

Phase

N/A

Condition

Muscular Dystrophy

Aging

Polymyositis (Inflammatory Muscle Disease)

Treatment

Placebo

Mitopure (Urolithin A)

Clinical Study ID

NCT06556706
2024-10182
  • Ages 65-85
  • All Genders

Study Summary

The study is a single-center, randomized, placebo-control double-blind study in frail older adults over 65yrs. to investigate the impact of Mitopure (Urolithin A) supplementation on muscle mitochondrial quality in frail older adults after 8-weeks of supplementation

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Frail (as defined by the Fried frailty criteria)nonsmoking participants in the agegroup of 65 to 85 years old, both male and female.

  • A body mass index between 18 to 35 kg/m2.

  • Not on any medications/living with medical conditions that would compromise thestudy outcome or the safety of the research participant.

  • Able to participate and willing to give written informed consent and to comply withthe study restrictions.

  • Willing to be assigned randomly either to the UA or the control group.

Exclusion

Exclusion Criteria:

Participants must not have:

  • Participated in a clinical trial within 90 days of screening or more than 4 times inthe previous year.

  • A history (within 3 months of screening) of alcohol consumption exceeding 2 standarddrinks per day on average (1 standard drink = 10 grams of alcohol).

  • A history or presence of allergy to 5-aminolevulinic acid or porphyrins.

  • A history or presence of allergy to lidocaine.

  • Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), orhuman immunodeficiency virus antibody (HIV Ab) at screening.

  • Unwillingness or inability to refrain from consuming alcohol within 48 hours beforeeach visit until the end of said visit.

  • Unwillingness or inability to refrain from consuming 8 or more units of xanthinecontaining beverages and foods per day during the entire study.

  • Unwillingness to not consume other mitochondrial supplements during the course ofthe study (such as CoQ10, reseveratrol, NR, NMN etc.) and pomegranate juice

  • unwillingness to not change diet or physical activity levels during the course ofthe study

  • Unwillingness or inability to undergo a muscle biopsy.

  • Underlying chronic disease, which in the opinion of the investigator, wouldinterfere with study participation or the validity of the measurements.

  • Unintentional weight loss ≤5% of regular body weight during the last 6 months.

  • Medication requirements that may interfere with the interpretation of the results.

  • Loss or donation of blood over 500mL three months prior (male subjects) or fourmonths prior (female subjects) to participating in the study.

  • Smoked (tobacco and/or marijuana mixed with tobacco (THC)) within 6 months prior tothe start of the study;

  • Abused drugs, medicine or alcohol within up to 30 days prior to the start of thestudy (Alcohol: more than 10 drinks a week, with more than 2 drinks a day most days;Drugs: THC, cocaine, opiates, amphetamines/methamphetamines, benzodiazepines,barbiturates, Buprenorphine, Creatin, Methadone metabolite, oxycodone,phencyclidine);

  • A positive COVID-19 test taken 1 week to 24h before study start date.

Study Design

Total Participants: 26
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
August 15, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • McGill University Health Center

    Montréal,
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.